6533b7d3fe1ef96bd125feca
RESEARCH PRODUCT
An observational, multicenter, retrospective, Italian Sarcoma Group (ISG) study of trabectedin in patients with advanced soft tissue sarcoma (STS).
Giovanni GrignaniAngela BuonadonnaGiuseppe BadalamentiEmanuela MarchesiAntonio PizzorussoElisabetta SetolaEmanuela PalmeriniTommaso De PasAlessandro ComandoneIrene QuattriniAntonella BrunelloPaolo G. CasaliPiero PicciToni IbrahimStefano FerrariVirginia FerraresiLaura MilesiBruno VincenziFederica GrossoGabriele Luppisubject
OncologyCancer Researchmedicine.medical_specialtyIfosfamidebusiness.industrySoft tissue sarcomaRetrospective cohort studymacromolecular substancesmedicine.diseasecarbohydrates (lipids)stomatognathic diseasesOncologyInternal medicineotorhinolaryngologic diseasesbacteriaMedicineObservational studyIn patientSarcomabusinessTrabectedinmedicine.drugdescription
e23502Background: Trabectedin (T) is approved for patients (pts) with STS after failure of anthracyclines (A) and ifosfamide (I), or pts unsuited to receive AI. ISG performed a retrospective study ...
year | journal | country | edition | language |
---|---|---|---|---|
2018-05-20 | Journal of Clinical Oncology |